Squawk on the Street

Palantir Slides, Pfizer-Novo Nordisk Bidding War Heats Up, Fund Giant to Vote Against Musk's $1T Pay Package 11/4/25

Nov 4, 2025
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Results Can Be Overridden By Valuation Fear

  • Palantir beat Q3 and raised revenue guidance yet the stock fell, showing valuation, not results, drove the selloff.
  • Alex Karp's public attacks on short sellers highlight how CEO behavior can influence investor sentiment.
INSIGHT

Profitability Doesn't Cancel Valuation Concerns

  • Jim Cramer called Palantir 'incredibly profitable' but questioned whether its market cap is justified.
  • The discussion shows high growth plus profitability still faces valuation scrutiny from investors.
INSIGHT

GLP-1 M&A Spurs Aggressive Bidding Tactics

  • Pfizer and Novo Nordisk entered a bidding war for Metsera, increasing takeover premiums in the GLP-1 space.
  • Novo's structure offered immediate cash plus CVRs, pressuring Pfizer and prompting legal action.
Get the Snipd Podcast app to discover more snips from this episode
Get the app